Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
44 studies found for:    "Prader-Willi syndrome"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
"Prader-Willi syndrome"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated Prader-Willi Syndrome and Appetite
Conditions: Hyperphagia;   Prader-Willi Syndrome
Intervention: Drug: Sandostatin LAR
2 Completed Hypoglycemia in Prader-Willi Syndrome
Conditions: Prader Willi Syndrome;   Hypoglycemia
Intervention: Other: Infants with Prader-Willi Syndrome
3 Not yet recruiting Oxytocin Trial in Prader-Willi Syndrome
Condition: Prader Willi Syndrome
Interventions: Drug: Intranasal oxytocin;   Other: Placebo
4 Recruiting Prader-Willi Syndrome Macronutrient Study
Conditions: Prader Willi Syndrome;   Syndromic Obesity;   Childhood Obesity
Interventions: Other: Low Carbohydrate diet;   Other: Low Fat diet
5 Completed Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome
Conditions: Prader-Willi Syndrome;   Self-Injurious Behavior
Intervention: Drug: Topiramate
6 Active, not recruiting Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome
Condition: Prader-Willi Syndrome
Intervention: Drug: Exenatide
7 Completed Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome
Conditions: Prader-Willi Syndrome;   Obesity
Intervention:
8 Completed Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?
Conditions: Prader-Willi Syndrome;   Growth Hormone Deficiency
Interventions: Drug: Growth hormone (Genotonorm® or Omnitrope®);   Procedure: DEXA, blood tests, H.G.P.O, osseous age.;   Procedure: biopsy
9 Recruiting Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study
Conditions: Prader Willi Syndrome;   Childhood Obesity
Intervention: Behavioral: Active Play at Home
10 Recruiting Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome
Condition: Prader-Willi Syndrome
Intervention: Device: Deep Brain Stimulation
11 Completed Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project
Conditions: Prader Willi Syndrome;   Obsessive-compulsive Disorder
Interventions: Behavioral: Cognitive-behavioral therapy;   Behavioral: Wait-list control
12 Completed Increased Expression of Adiponectin Receptor 2 in the Mononuclear Cells in Children With Prader-Willi Syndrome
Conditions: Obesity;   Prader-Willi Syndrome
Intervention:
13 Unknown † Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome
Condition: Prader-Willi Syndrome
Intervention: Drug: Norditropin SimpleXx
14 Terminated
Has Results 		Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)
Condition: Prader-Willi Syndrome
Interventions: Drug: Octreotide;   Drug: Placebo
15 Completed Plasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Willi Syndrome
Conditions: Prader-Willi Syndrome;   Obesity
Intervention:
16 Active, not recruiting Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
Condition: Prader-Willi Syndrome
Interventions: Drug: DCCR;   Drug: Placebo
17 Not yet recruiting Ph 2 Trial to Evaluate Safety & Efficacy of RM-493 in Obese Patients With Prader-Willi Syndrome
Condition: Prader-Willi Syndrome
Interventions: Drug: RM-493;   Drug: Placebo
18 Not yet recruiting Experience With Growth Hormone (GH) in Children Under 2 Years With Prader-Willi Syndrome (PWS) in the Pediatric Endocrine Department of the Hospital of Sabadell
Condition: Prader-Willi Syndrome
Intervention: Drug: Recombinant Somatropin
19 Recruiting Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
Conditions: Prader-Willi Syndrome;   Obesity
Interventions: Drug: ZGN-440 for Injectable Suspension;   Drug: ZGN-440 Placebo for Injectable Suspension
20 Completed Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity
Conditions: Prader-Willi Syndrome;   Obesity
Interventions: Other: Group 1;   Other: Group 2
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years